These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18611063)

  • 41. Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.
    Goto K; Goto S; Fujii H; Watanabe K; Kono K; Nishi S
    J Bone Miner Metab; 2019 Nov; 37(6):1075-1082. PubMed ID: 31214836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapeutic use of the phosphate binder lanthanum carbonate.
    Barton Pai A; Conner TA; McQuade CR
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):71-81. PubMed ID: 19236230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
    Schumacher SP; Schurgers LJ; Vervloet MG; Neradova A
    Nephrology (Carlton); 2019 Feb; 24(2):221-226. PubMed ID: 29479762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Expert Opin Pharmacother; 2005 Feb; 6(2):319-28. PubMed ID: 15757427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats.
    Bervoets AR; Oste L; Behets GJ; Dams G; Blust R; Marynissen R; Geryl H; De Broe ME; D'Haese PC
    Bone; 2006 Jun; 38(6):803-10. PubMed ID: 16412714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate.
    Hyodo T; Kawakami J; Mikami N; Wakai H; Ishii D; Yoshida K; Iwamura M; Hida M; Kurata Y
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():14-7. PubMed ID: 24953761
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lanthanum Carbonate - A New Phosphate Binding Drug in Advanced Renal Failure.
    Aaseth J; Bjorke-Monsen AL
    Curr Med Chem; 2018; 25(1):113-117. PubMed ID: 28486924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D; Donne RL; Hutchison AJ
    Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients.
    How PP; Anattiwong P; Mason DL; Arruda JA; Lau AH
    Hemodial Int; 2011 Jan; 15(1):95-9. PubMed ID: 21138519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lanthanum carbonate.
    Joy MS; Kshirsagar A; Candiani C; Brooks T; Hudson JQ
    Ann Pharmacother; 2006 Feb; 40(2):234-40. PubMed ID: 16449551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure.
    Bervoets AR; Behets GJ; Schryvers D; Roels F; Yang Z; Verberckmoes SC; Damment SJ; Dauwe S; Mubiana VK; Blust R; De Broe ME; D'Haese PC
    Kidney Int; 2009 Feb; 75(4):389-98. PubMed ID: 19052535
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.
    Pennick M; Poole L; Dennis K; Smyth M
    Ren Fail; 2012; 34(3):263-70. PubMed ID: 22250993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
    Shinoda T; Yamasaki M; Chida Y; Takagi M; Tanaka Y; Ando R; Suzuki T; Tagawa H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():29-34. PubMed ID: 23586510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.